Is Hims & Hers Stock a Buy Now?
Hims & Hers reported another strong quarter this month as its growth rate remains above 50%. The company raised its forecast for the year as well.
Hims & Hers Health, Inc. (HIMS) Q3 2023 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Alice Lopatto - VP, IR Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe -...
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
Hims and Hers narrows loss, raises revenue guidance for the year
Shares of Hims & Hers Health Inc. HIMS, -3.09% rose more than 3% in the extended session Monday after the telehealth company narrowed its quarterly loss and raised its sales guidance for the year, ...
Hims & Hers: A Promising Company With Resolvable Challenges
While HIMS showcases robust performance, its ability to navigate and mitigate associated risks will be pivotal in securing its future success. Major risks revolve around customer service issues, ri...
Hims & Hers: Specialization Is The Secret To Great Growth
Hims & Hers Health offers personalized and customized telehealth services, specializing in niche treatments for hair loss, erectile dysfunction, skincare, acne, and mental health. The company has e...
Is Hims & Hers Health Stock a Buy Now?
Hims & Hers is cutting prices, but profit margins are rising. The company is cash flow positive, with plenty of cash on the balance sheet.
Hims & Hers Health: Risks Remain, But Upgrading To Buy
Hims & Hers reported strong earnings and raised its full-year guidance, but its stock continues to decline. Hims & Hers is focusing on personalization and expanding into new categories to drive gro...
Hims & Hers: Myopic Shorts, Absurdly Cheap
Hims & Hers Health, Inc. is rapidly growing and becoming more profitable, making it a cheaply valued stock with minimal risk. A recent short report questions Hims' ability to turn customer acquisit...
The Market Is Wrong On Hims & Hers Health
Hims & Hers managed to grow revenue every year by at least 80%. However, it's still trading below its initial price when became publicly traded via SPAC. The company is targeting lofty growth targe...
Is This Underrated SPAC Deal Stock a No-Brainer Buy?
Hims & Hers Health went public through a SPAC merger a couple of years ago. Since then, the stock is down 60%.
This Fast-Growing Company Is the Latest to Launch a Weight-Loss Business
The market for weight management could be worth close to $300 billion by the end of the decade. Hims & Hers is planning to launch a weight-loss business by January.
Hims & Hers: Buying With Both Fists (Double Rating Upgrade)
Hims & Hers Health reported a strong Q2 and raised guidance, but the stock has sold off sharply. The company is expanding into new product categories such as heart health and weight management. We ...
Hims & Hers: Divergence Between Fundamentals And Valuation
Q2 Revenue beat analyst estimates by $3M. Gross Margin improved despite price cuts. Management raised guidance by $20M, which also beat estimates by $19M.
Related Companies